Patients report improved comfort with new artificial tear


Source/Disclosures

Source:

Ng A, et al. Review of symptomatic relief and tear film kinetic stability of I-Drop MGD eye drops. Presented at: Optometry’s Meeting; June 15-18, 2022; Chicago


Disclosures: Disclosure: Ng indicated that I-MED Pharma provided financial and material support for the study.


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

CHICAGO — Participants in a pilot study rated higher comfort and soothing with I-Drop MGD compared to their regular eye drops, according to a poster presented at the optometry meeting.

I-Drop MGD, manufactured by I-MED Pharma in Montreal, is a preservative-free artificial tear that contains viscoadaptive hyaluronic acid, a lipid component (phosphorylcholine) and glycerin to support integration, stabilization and improved tear film, in addition to hydration of the ocular surface, lead author Alison Ng, PhD, BSc (Hons), MCOptom, FAAO, said Healio.

The researchers recruited 10 participants with established dry eye who habitually used artificial tears or eye lubricating drops at least once a day for the past 30 days to manage their symptoms, Ng, a clinician scientist at the Center for Ocular Research & Education from the University of Waterloo School of Optometry & Vision Science, said.

In the second part of this two-part study, participants were given one bottle of I-Drop MGD to be used bilaterally at least once daily for 7 days and were asked to self-report comfort, dryness, relief and quality of vision.

The researchers also collected Ocular Surface Disease Index (OSDI) and Standard Patient Evaluation of Eye Dryness Questionnaire (SPEED) scores from the participants.

“These ratings were compared to ratings collected after 7 days of using the participants’ usual eye drops, prior to their exposure to I-Drop MGD,” Ng said.

Subjective comfort and soothing ratings were significantly higher with I-Drop MGD compared to participants’ usual eye drops, she said.

“Although improvements in subjective ratings of dryness and quality of vision were observed, these did not reach statistical significance,” Ng said. “There was a statistically significant and clinically relevant reduction of 12 points in OSDI score after using I-Drop MGD for 7 days compared to usual drops. A statistically significant reduction of 4 points in the SPEED score was observed.

Comments are closed.